Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 11, 2007 - Issue 12
Submit an article Journal homepage
142
Views
14
CrossRef citations to date
0
Altmetric
Review

The role of estrogen receptor in melanoma

Atsushi Tanemura These authors contributed equally to the manuscript.; John Wayne Cancer Institute, Department of Molecular Oncology, 2200 Santa Monica Blvd., Santa Monica, CA 90404, USA +1 310 449 5282; [email protected]
, MD PhD,
Anneke Q van Hoesel These authors contributed equally to the manuscript.; John Wayne Cancer Institute, Department of Molecular Oncology, 2200 Santa Monica Blvd., Santa Monica, CA 90404, USA +1 310 449 5282; [email protected]
, MD,
Takuji Mori John Wayne Cancer Institute, Department of Molecular Oncology, 2200 Santa Monica Blvd., Santa Monica, CA 90404, USA +1 310 449 5282; [email protected]
, MD PhD,
Terrance Yu John Wayne Cancer Institute, Department of Molecular Oncology, 2200 Santa Monica Blvd., Santa Monica, CA 90404, USA +1 310 449 5282; [email protected]
&
Dave SB Hoon John Wayne Cancer Institute, Department of Molecular Oncology, 2200 Santa Monica Blvd., Santa Monica, CA 90404, USA +1 310 449 5282; [email protected]
, PhD
Pages 1639-1648 | Published online: 18 Nov 2007

Bibliography

  • JEMAL A, SIEGEL R, WARD E, MURRAY T, XU J, THUN MJ: Cancer statistics, 2007. CA Cancer J. Clin. (2007) 57:43-66.
  • FRANCESCHI S, BARON AE, LA VECCHIA C: The influence of female hormones on malignant melanoma. Tumori (1990) 76:439-449.
  • LENS MB, EISEN TG: Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin. Pharmacother. (2003) 4:2205-2211.
  • BODENHAM DC, HALE B: Malignant melanoma. Endocrine Therapy in Malignant Disease. Edited by London, Saunders WB, Co., Ltd. (1972):377-383.
  • DEVITA VT Jr, FISHER RI: Natural history of malignant melanoma as related to therapy. Cancer Treat. Rep. (1976) 60:153-157.
  • HOUGHTON AN, FLANNERY J, VIOLA MV: Malignant melanoma of the skin occurring during pregnancy. Cancer (1981) 48:407-410.
  • SUTHERLAND CM, LOUTFI A, MATHER FJ, CARTER RD, KREMENTZ ET: Effect of pregnancy upon malignant melanoma. Surg. Gynecol. Obstet. (1983) 157:443-446.
  • SMITH MA, FINE JA, BARNHILL RL, BERWICK M: Hormonal and reproductive influences and risk of melanoma in women. Int. J. Epidemiol. (1998) 27:751-757.
  • SILIPO V, DE SIMONE P, MARIANI G, BUCCINI P, FERRARI A, CATRICALA C: Malignant melanoma and pregnancy. Melanoma Res. (2006) 16:497-500.
  • LENS MB, ROSDAHL I, AHLBOM A et al.: Effect of pregnancy on survival in women with cutaneous malignant melanoma. J. Clin. Oncol. (2004) 22:4369-4375.
  • GRIN CM, DRISCOLL MS, GRANT-KELS JM: The relationship of pregnancy, hormones, and melanoma. Semin. Cutan. Med. Surg. (1998) 17:167-171.
  • ROSE C, PEDERSEN L, MOURIDSEN HT: Endocrine treatment with anti-estrogen, anti-androgen or progestagen of advanced malignant melanoma: three consecutive Phase II trials. Eur. J. Cancer Clin. Oncol. (1985) 21:1171-1174.
  • FISHER RI, NEIFELD JP, LIPPMAN ME: Oestrogen receptors in human malignant melanoma. Lancet (1976) 2:337-339.
  • SPEIRS V, CARDER PJ, LANE S, DODWELL D, LANSDOWN MR, HANBY AM: Oestrogen receptor β: what it means for patients with breast cancer. Lancet Oncol. (2004) 5:174-181.
  • PETTERSSON K, GUSTAFSSON JA: Role of estrogen receptor β in estrogen action. Annu. Rev. Physiol. (2001) 63:165-192.
  • YAGER JD, DAVIDSON NE: Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. (2006) 354:270-282.
  • ZHANG D, TRUDEAU VL: Integration of membrane and nuclear estrogen receptor signaling. Comp. Biochem. Physiol. A Mol. Integr. Physiol. (2006) 144:306-315.
  • SHAO W, BROWN M: Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res. (2004) 6:39-52.
  • PEDRAM A, RAZANDI M, WALLACE DC, LEVIN ER: Functional estrogen receptors in the mitochondria of breast cancer cells. Mol. Biol. Cell (2006) 17:2125-2137.
  • COUSE JF, LINDZEY J, GRANDIEN K, GUSTAFSSON JA, KORACH KS: Tissue distribution and quantitative analysis of estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) messenger ribonucleic acid in the wild-type and ERβ-knockout mouse. Endocrinology (1997) 138:4613-4621.
  • OSBORNE CK: Steroid hormone receptors in breast cancer management. Breast Cancer Res. Treat. (1998) 51:227-238.
  • BEATSON G: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment. Lancet (1896) 2:104-107.
  • Tamoxifen for early breast cancer: an overview of the randomised trials. Early breast cancer trialists' collaborative group. Lancet (1998) 351:1451-1467.
  • CUNAT S, HOFFMANN P, PUJOL P: Estrogens and epithelial ovarian cancer. Gynecol. Oncol. (2004) 94:25-32.
  • SHANG Y: Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat. Rev. Cancer (2006) 6:360-368.
  • CARRUBA G: Estrogens and mechanisms of prostate cancer progression. Ann. NY Acad. Sci. (2006) 1089:201-217.
  • DI LEO A, MESSA C, CAVALLINI A, LINSALATA M: Estrogens and colorectal cancer. Curr. Drug Targets Immune Endocr. Metabol. Disord. (2001) 1:1-12.
  • WALKER MJ, BEATTIE CW, PATEL MK, RONAN SM, DAS GUPTA TK: Estrogen receptor in malignant melanoma. J. Clin. Oncol. (1987) 5:1256-1261.
  • COHEN C, DEROSE PB, CAMPBELL WG, SCHLOSNAGLE DC, SGOUTAS D: Estrogen receptor status in malignant melanoma. Am. J. Dermatopathol. (1990) 12:562-564.
  • SCHMIDT AN, NANNEY LB, BOYD AS, KING LE Jr, ELLIS DL: Oestrogen receptor-β expression in melanocytic lesions. Exp. Dermatol. (2006) 15:971-980.
  • SINGH MN, STRINGFELLOW HF, PARASKEVAIDIS E, MARTIN-HIRSCH PL, MARTIN FL: Tamoxifen: important considerations of a multi-functional compound with organ-specific properties. Cancer Treat. Rev. (2007) 33:91-100.
  • GELMANN EP: Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin. Oncol. (1997) 24(S1):65-70.
  • JONES JA, ALBRIGHT KD, CHRISTEN RD, HOWELL SB, MCCLAY EF: Synergy between tamoxifen and cisplatin in human melanoma cells is dependent on the presence of antiestrogen-binding sites. Cancer Res. (1997) 57:2657-2660.
  • CREAGAN ET, INGLE JN, GREEN SJ, AHMANN DL, JIANG NS: Phase II study of tamoxifen in patients with disseminated malignant melanoma. Cancer Treat. Rep. (1980) 64:199-201.
  • LENS MB, REIMAN T, HUSAIN AF: Use of tamoxifen in the treatment of malignant melanoma. Cancer (2003) 98:1355-1361.
  • COCCONI G, BELLA M, CALABRESI F et al.: Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N. Engl. J. Med. (1992) 327:516-523.
  • O'DAY SJ, GAMMON G, BOASBERG PD et al.: Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2. Granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J. Clin. Oncol. (1999) 17:2752-2761.
  • PIANTELLI M, MAGGIANO N, RICCI R et al.: Tamoxifen and quercetin interact with type II estrogen binding sites and inhibit the growth of human melanoma cells. J. Invest. Dermatol. (1995) 105:248-253.
  • PIANTELLI M, RANELLETTI FO, MAGGIANO N: Tamoxifen and Quercetin in melanoma cell growth. role of type II estrogen binding sites. Maio M (Ed.), IOS Press, Amsterdam, The Netherlands (1996):248-253.
  • LAMA G, ANGELUCCI C, BRUZZESE N et al.: Sensitivity of human melanoma cells to oestrogens, tamoxifen and quercetin: is there any relationship with type I and II oestrogen binding site expression? Melanoma Res. (1998) 8:313-322.
  • KANDA N, WATANABE S: 17β-estradiol, progesterone, and dihydrotestosterone suppress the growth of human melanoma by inhibiting interleukin-8 production. J. Invest. Dermatol. (2001) 117:274-283.
  • KANTER-LEWENSOHN L, GIRNITA L, GIRNITA A et al.: Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway. Mol. Cell Endocrinol. (2000) 165:131-137.
  • HERMAN JG, BAYLIN SB: Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. (2003) 349:2042-2054.
  • HOON DS, SPUGNARDI M, KUO C, HUANG SK, MORTON DL, TABACK B: Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene (2004) 23:4014-4022.
  • ISSA JP, OTTAVIANO YL, CELANO P, HAMILTON SR, DAVIDSON NE, BAYLIN SB: Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat. Genet. (1994) 7:536-540.
  • FUJII S, TOMINAGA K, KITAJIMA K et al.: Methylation of the oestrogen receptor gene in non-neoplastic epithelium as a marker of colorectal neoplasia risk in longstanding and extensive ulcerative colitis. Gut (2005) 54:1287-1292.
  • OTTAVIANO YL, ISSA JP, PARL FF, SMITH HS, BAYLIN SB, DAVIDSON NE: Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. (1994) 54:2552-2555.
  • MORI T, MARTINEZ SR, O'DAY SJ et al.: Estrogen receptor-α methylation predicts melanoma progression. Cancer Res. (2006) 66:6692-6698.
  • GIACINTI L, CLAUDIO PP, LOPEZ M, GIORDANO A: Epigenetic information and estrogen receptor α expression in breast cancer. Oncologist (2006) 11:1-8.
  • FERGUSON AT, LAPIDUS RG, BAYLIN SB, DAVIDSON NE: Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res. (1995) 55:2279-2283.
  • YANG X, FERGUSON AT, NASS SJ et al.: Transcriptional activation of estrogen receptor α in human breast cancer cells by histone deacetylase inhibition. Cancer Res. (2000) 60:6890-6894.
  • LEADER JE, WANG C, FU M, PESTELL RG: Epigenetic regulation of nuclear steroid receptors. Biochem. Pharmacol. (2006) 72:1589-1596.
  • YANG X, PHILLIPS DL, FERGUSON AT, NELSON WG, HERMAN JG, DAVIDSON NE: Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells. Cancer Res. (2001) 61:7025-7029.
  • MUNSTER P, MARCHION D, BICAKU E et al.: Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J. Clin. Oncol. (2007) 25:1979-1985.
  • DAUD A, SCHMITT M, MARCHION D et al.: Phase I trial of a sequence-specific combination of the HDAC inhibitor, vorinostat (SAHA) followed by doxorubicin in advanced solid tumor malignancies. Am. Soc. Clin. Oncol. (2007) 25:3502.
  • TABACK B, HOON DS: Circulating nucleic acids in plasma and serum: past, present and future. Curr. Opin. Mol. Ther. (2004) 6:273-278.
  • JIANG SY, JORDAN VC: Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J. Natl. Cancer Inst. (1992) 84:580-591.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.